Pharmaceuticals News and Research

RSS

Ampio Pharmaceuticals receives approval to trade under new stock trading symbol "AMPE"

Ampio Pharmaceuticals, Inc., announced it has received approval for a new stock trading symbol from FINRA Operations. Effective March 31, 2010, Ampio Pharmaceuticals, Inc. will trade under the symbol "AMPE," and Ampio's common stock will carry a new CUSIP number, 03209T 109. The symbol change follows the March 24 change in the company's corporate name from Chay Enterprises, Inc. to Ampio Pharmaceuticals, Inc., and its reincorporation in Delaware.

31 Mar 2010

AFFiRiS AG develops PD01 vaccine for Parkinson's disease

Today AFFiRiS AG announced an important step forward in the development of its vaccine for Parkinson's disease. The vaccine, known as PD01, has undergone numerous preclinical tests which have confirmed its principle of action ("Proof of Concept").

31 Mar 2010

International pharmaceutical company orders Microsoft Dynamics AX for Process Industries from Acando

“Acando has extensive experience from projects in the life science sector. When we combine that with our deep application knowledge, we are hard to beat”

31 Mar 2010

Novel oral anticoagulants to drive venous thromboembolism drug market to $5 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launches and widespread uptake of novel oral anticoagulants will drive the venous thromboembolism drug market to nearly double from $2.9 billion in 2008 to more than $5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

31 Mar 2010

AAN awards 2010 Dreifuss-Penry Epilepsy Award to Vanderbilt University School of Medicine researcher

The American Academy of Neurology (AAN) is awarding the 2010 Dreifuss-Penry Epilepsy Award to Martin J. Gallagher MD, PhD, with Vanderbilt University School of Medicine. Gallagher will receive the award during the AAN's 62nd Annual Meeting in Toronto, held April 10 through April 17, 2010.

31 Mar 2010

Sanofi Pasteur accelerates deployment of Intercim's Pertinence Suite MOM software solution

Intercim, announces that Sanofi Pasteur, the vaccines division of the Sanofi-aventis Group, is accelerating the use of Pertinence Suite, Manufacturing Operations Management (MOM) software solution, within the European and North American sites of the worldwide leader of vaccines.

31 Mar 2010

Nymox Pharmaceutical's NX-1207 human clinical trials for HCC demonstrate favorable safety data

Nymox Pharmaceutical Corporation outlined today the Company's development program for the Company's lead drug candidate, NX-1207, currently in Phase 3 trials in the U.S. for the treatment of benign prostatic hyperplasia (BPH). The drug has been successful in a series of blinded controlled multi-center U.S. clinical trials where it has been found to produce improvements that are about double that reported for currently approved BPH drugs.

31 Mar 2010

Despite stagnant economy, total employment in Ohio's bioscience sector increased by 2.8%

Employment in Ohio's biosciences sector is on the rise across the state according to a report released today by BioOhio, a non-profit organization supported by the Thomas Edison Program of the Ohio Department of Development.

31 Mar 2010

BioSante Pharmaceuticals completes Azur Pharma Elestrin royalty buydown

BioSante Pharmaceuticals, Inc. today announced the successful completion of the Azur Pharma Elestrin royalty buydown, and financial results for the year ended December 31, 2009.

31 Mar 2010

Astellas Pharma extends all-cash tender offer of OSI Pharmaceuticals

Astellas Pharma Inc. announced today that it has extended its all-cash tender offer for $52 per share for all of the currently outstanding shares of common stock (including the associated stock purchase rights) of OSI Pharmaceuticals to 11:59 p.m. New York City time on Friday, April 23, 2010, unless further extended.

31 Mar 2010

USPTO issues Notice of Allowance for menadione to prevent skin rash in patients taking EGFR inhibitors

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for the use of menadione to prevent and treat skin rash in patients taking biologic and small molecule epidermal growth factor receptor inhibitors, such as Erbitux® and Tarceva®, for anti-cancer therapy.

31 Mar 2010

NKF 2010 Spring Clinical Meeting: Multiple posters on Hematide/peginesatide to be presented

Affymax, Inc. and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced multiple posters on Hematide™/peginesatide have been accepted for presentation at the National Kidney Foundation (NKF) 2010 Spring Clinical Meeting taking place April 13-17, 2010 in Orlando, Florida. Hematide is an investigational agent for the treatment of anemia in chronic renal failure (also referred to as renal anemia).

31 Mar 2010

Daily Nation examines fundraising efforts in Kenya to support patients living with HIV/AIDS

The Daily Nation examines efforts underway in Kenya to raise money for patients living with HIV/AIDS who are in need antiretroviral (ARV) therapy.

31 Mar 2010

Praxis extends patient recruitment services for international HCV study

Praxis, a company specializing in centralized patient recruitment for clinical research studies, is extending patient recruitment services to a top 20 pharmaceutical company for an international Hepatitis C Virus study. The study explores an investigational drug's effectiveness for this condition affecting almost 4 million Americans.

31 Mar 2010

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

YM BioSciences Inc., announced that it has received ethics board approval to expand enrolment in its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis, a chronic debilitating condition, where patient's bone marrow is replaced by scar tissue.

31 Mar 2010

Access Pharmaceuticals, bioRASI sign collaborative agreement to develop Cobalamin oral insulin product

ACCESS PHARMACEUTICALS, INC. signed a collaborative development agreement with bioRASI, LLC, a full-service global CRO specializing in the accelerated development of novel therapeutics, to facilitate clinical development for its Cobalamin™-based oral insulin and other Cobalamin-based products.

31 Mar 2010

Titan Pharmaceuticals commences Phase 3 study of Probuphine for opioid addiction

Titan Pharmaceuticals, Inc. today announced the initiation of a randomized, placebo and active controlled, multi-center Phase 3 clinical study of Probuphine in the treatment of opioid addiction. This confirmatory Phase 3 study will be conducted at approximately 23 sites in the United States and randomize approximately 250 patients into three arms: Probuphine (100 patients), Suboxone® (100 patients) and placebo (50 patients).

31 Mar 2010

Hospira acquires Orchid's injectables formulations business

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has completed the acquisition of the generic injectable pharmaceuticals business of Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $400 million.

31 Mar 2010

NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss

NovaBay Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported full-year and fourth quarter financial results for 2009. The company also highlighted recent progress of its proprietary and partnered development programs.

30 Mar 2010

Savient Pharmaceuticals' resubmission of BLA for KRYSTEXXA accepted for FDA review

Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has acknowledged receipt of and accepted for review the March 15, 2010 resubmission of the Biologics License Application for KRYSTEXXA™ (pegloticase), a treatment for chronic gout in patients refractory to conventional therapy.

30 Mar 2010

Pharmaceuticals News and Research

Ampio Pharmaceuticals receives approval to trade under new stock trading symbol "AMPE"

AFFiRiS AG develops PD01 vaccine for Parkinson's disease

International pharmaceutical company orders Microsoft Dynamics AX for Process Industries from Acando

Novel oral anticoagulants to drive venous thromboembolism drug market to $5 billion in 2018

AAN awards 2010 Dreifuss-Penry Epilepsy Award to Vanderbilt University School of Medicine researcher

Sanofi Pasteur accelerates deployment of Intercim's Pertinence Suite MOM software solution

Nymox Pharmaceutical's NX-1207 human clinical trials for HCC demonstrate favorable safety data

Despite stagnant economy, total employment in Ohio's bioscience sector increased by 2.8%

BioSante Pharmaceuticals completes Azur Pharma Elestrin royalty buydown

Astellas Pharma extends all-cash tender offer of OSI Pharmaceuticals

USPTO issues Notice of Allowance for menadione to prevent skin rash in patients taking EGFR inhibitors

NKF 2010 Spring Clinical Meeting: Multiple posters on Hematide/peginesatide to be presented

Daily Nation examines fundraising efforts in Kenya to support patients living with HIV/AIDS

Praxis extends patient recruitment services for international HCV study

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

Access Pharmaceuticals, bioRASI sign collaborative agreement to develop Cobalamin oral insulin product

Titan Pharmaceuticals commences Phase 3 study of Probuphine for opioid addiction

Hospira acquires Orchid's injectables formulations business

NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss

Savient Pharmaceuticals' resubmission of BLA for KRYSTEXXA accepted for FDA review

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence